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Apoptosis is a physiological process for acttve cell removal. One of its hallmarks is an increased cytosolic Ca2’ content. Several genes involved 
m apoptosis control have been identified, but their mode of action is not understood in detail. Apoptosis may relate to oncogenesis, in that some 
malignant umors may grow because genes engaged in apoptosis control are altered. L929 cells overexpressing the proto-oncogen bcl-2 have an 
increased mitochondrial membrane potential (dv), as have many carcinoma cells. bcl-2 protects L929 cells against apoptosis caused by pro-oxidant- 
induced mitochondrial Ca2’ ‘cycling’ and increased cytosolic Ca” levels. Nerve growth factor, which induces catalase, and inhibitors of mitochon- 
driat Ca2+ release also prevent apoptosis. It is suggested that a pro-oxidant-induced Ca2+ release from mitochondria, followed by Ca2+ cycling and 
ATP depletion, is a common basic event during apoptosis. Accordmgly, maintenance of dv stabilizes mitochondria, thereby prevents apoptosis, 
and may confer increased growth potential to cells. 
dvv; bcl-2 Proto-oncogen; Tumor necrosis factor; Nerve growth factor; Catalase 
1. CELLULAR CA’+ HOMEOSTASIS 
Free calcium ions play a prominent role in the regula- 
tion of many enzyme systems and serve the fundamental 
function of an intracellular messenger [l]. To this end, 
fine tuning of the Ca2+ concentration is required, which 
is achieved by binding of Ca2+ to non-membraneous 
proteins, and by membrane-bound Ca2’ transport sys- 
tems. The latter carry the main burden of Ca” regula- 
tion. They operate in the plasma membrane, the endo- 
plasmic (sarcoplasmic) reticulum, in the nucleus, and in 
mitochondria, and use, with the exception of the mito- 
chondrial transport system, ATP hydrolysis as the driv- 
ing force for Ca2+ transport. In light of the importance 
of the Ca2’ homeostasis it is not surprising that its dis- 
turbance can be fatal for the cell (reviewed in [2]). 
2. MITOCHONDRIAL CA2+ TRANSPORT 
Mitochondrial Ca2+ uptake occurs via a specific path- 
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way and is driven by the mitochondrial membrane po- 
tential (dw) (for review, see [3]). Intramitochondrially 
Ca2+ regulates three dehydrogenases and possibly nu- 
cleic acid synthesis. In addition, mitochondria are a 
safety device against a flooding of the cytosol with Ca2+, 
because they can take up and store transiently large 
amounts of Ca2’ with impunity. 
In order to prevent dysregulation of mitochondrial 
enzymes and calcification of the organelle, mitochon- 
dria must be able to release Ca2+. Release from intact 
mitochondria occurs via a specific route in exchange 
with Na’ or H’, but in de-energized mitochondria re- 
lease may also occur by reversal of the uptake pathway. 
Under normal conditions mitochondria slowly take up 
and release (‘cycle’) Ca2’, and do so with little energy 
expenditure. However, under certain conditions, e.g. 
with high Ca2’ loads and oxidative stress, Ca2’ cycling 
becomes excessive and results in an increased energy 
demand and a dramatic fall of Av. This leadsto a de- 
creased ability of mitochondria to retain Ca2’, their 
uncoupling, and an impairment of mitochondrial ATP 
synthesis, which in turn deprives the cell of the fuel for 
the Ca2’-sequestering ATPases. As a consequence, the 
cytosolic Ca2’ content rises drastically. 
3. PRO-OXIDANTS CAUSE CA2+ RELEASE 
FROM MITOCHONDRIA 
Pro-oxidants such as hydrogen peroxide or organic 
peroxides stimulate the Na+-independent Ca2+ release 
104 Published by Elsevrer Science Publishers B. V. 
Volume 325, number 1,2 FEBS LETTERS June 1993 
from intact mitochondria, as shown in isolated organ- 
elles and in cells (for review, see [4]). This release re- 
quires pyridine nucleotide oxidation followed by hy- 
drolysis of NAD* to ADPribose and nicotinamide, and 
is inhibited by agents which prevent NAD+ hydrolysis 
or protein mono(ADPribosyl)ation, e.g. by cyclosporin 
A or m-iodobenzylguanidine. These agents protect iso- 
lated mitochondria [5-71, cells [8-lo], and organs [ll] 
against Ca*‘-induced damage. 
4. APOPTOSIS, ONCOGENESIS, PRO-OXIDANTS 
AND CA*+ 
Apoptosis (programmed cell death, physiological cell 
death)* is a fundamental process observed during organ 
and body sculpting and control of immune cells [12-l 61, 
but may possibly be a general property of most cells 
[ 17,181. Cells go into apoptosis as a response to a variety 
of primary triggers such as appearance or disappear- 
ance of hormonal signals, changes in cytokine and 
growth factor levels, or increased cytosolic Ca*+ levels. 
Apoptosis is often, but not always, accompanied by an 
activation of (a) Ca*+-dependent endonuclease(s) and a 
characteristic fragmentation of nuclear DNA. 
Apoptosis requires an active participation of cellular 
components, and several cellular genes (bcl-2, c-myc, 
~53, TRPM-2, RP-2, RP-8, APO-IIFAS, ted-3, ted-4, 
ted-9) have been identified which can control (suppress 
or stimulate) it. For example, the proto-oncogen bcl-2 
suppresses apoptosis induced by growth factor depriva- 
tion or viruses [19-231. The mechanisms by which such 
a control is achieved are not clear. An important first 
hint comes from the recent report [24] that L929 cells 
overexpressing bcl-2, which is mainly localized in the 
inner mitochondrial membrane [25] but also in the nu- 
clear envelope and endoplasmic reticulum [26,27], have 
an increased dv and are therefore protected against 
apoptotic cell killing (see below). In the present context 
it is important to note that mitochondria of many carci- 
noma cells have an increased dy/ [28]. Also viral genes 
can protect cells from going into apoptosis [29-311 or 
stimulate it [23]. 
Apoptosis was in the past mainly seen as a means to 
remove cells. However, it is now realized that inhibition 
of apoptosis may contribute to oncogenesis [32,33], be- 
cause tissue homeostasis is a fragile balance between cell 
proliferation and cell death. 
The importance of Ca*’ in cell proliferation has al- 
ready been recognized many years ago [34,35]. For in- 
stance, oncogenic growth factors such as epidermal or 
platelet-derived growth factor cause an increase of the 
cytosolic Ca*’ level by stimulating Ca*+ influx into the 
cell or by release of Ca*’ from the endoplasmic reticu- 
lum through turnover of phosphatidyl inositols. 
Pro-oxidants such as H,O, and organic peroxides 
may play an important role in cell proliferation (for 
reviews see [36,37]). Depending on the level of exposure, 
pro-oxidants can both stimulate or inhibit proliferation 
of fibroblasts [38]. Pro-oxidants may act through mobi- 
lization of Ca*+, as demonstrated in mouse epidermal 
cells [39]. In addition, protein kinases, especially protein 
kinase C [40] and the insulin receptor tyrosine kinase 
[41,42], can be activated during exposure of cells to 
oxidative stress. Hence, both an increase in the cytosolic 
Ca*’ concentration and an activation of protein kinase 
C may be critically involved in pro-oxidant-mediated 
cell proliferation. It is also worth noting that extracellu- 
larly generated oxygen radicals cause an increase in the 
rate of transcription of c-myc and c&s genes [43], and 
that their expression is inducible by Ca*+ [44] as well as 
protein kinase C [45]. 
5. THE ROLE OF MITOCHONDRIAL CA’+ 
Tumor necrosis factor c1 (TNF) induces apoptosis in 
L929 cells by stimulating superoxide radical production 
in mitochondria [46,47]. Resistant L929 cells, produced 
by culturing wild type cells in media containing increas- 
ing TNF concentrations, have a diminished ability to 
produce superoxide in response to TNF [47]. TNF-in- 
duced superoxide production and cell killing require 
mitochondrial Ca*+ cycling because they are suppressed 
by omission of Ca*+ or in the presence of EGTA, and 
by Ruthenium red, an inhibitor of the mitochondrial 
Ca*’ uptake pathway [47]. Increased mitochondrial su- 
peroxide production is followed by a decrease in mito- 
chondrial functions as illustrated by the fall of dehydro- 
genase activity and ATP depletion [47]. L929 cells over- 
expressing the proto-oncogen bcl-2 have mitochondria 
with elevated dv, and are much less sensitve to TNF 
[24]. Indeed, nigericin, an ionophore which raises dy/, 
protects wild type cells even at high TNF concentrations 
[24]. These results suggest hat TNF mediates apoptosis 
in L929 cells by stimulating mitochondrial Ca*’ cycling, 
and that bcl-2 protects against it. bcl-2 also blocks Ca*‘- 
triggered death in thymocytes [48,49] and cultured pan- 
creatic cells (J.-C. Martinou, personal communication), 
and prevents apoptosis when expressed in Caenorhabdi- 
tis elegans [50]. However, it should also be mentioned 
that bcl-2 protects against apoptosis, induced by the 
protein kinase inhibitor staurosporine or by serum de- 
privation, in cells lacking mitochondrial DNA and there- 
fore mitochondrial respiration [5 11. 
Neurons require the presence of nerve growth factor 
(NGF) to remain viable in cell culture, but neurons 
overexpressing bcl-2 do not need NGF to survive [52]. 
NGF protects neurons in vitro against perturbations of 
the pro-oxidant-antioxidant balance by the induction 
of catalase and glutathione transferase [53], and cata- 
lase enables resting chondrocytes to survive when 
grown in the absence of growth factors in serum-free 
culture [54]. 
Pro-oxidants like tert-butyl hydroperoxide, cumene 
hydroperoxide, or 3,5-dimethyl-N-acetyl-p-benzoqui- 
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Fig. 1. Pro-oxidants and mitochondrial Car’ in apoptosis and oncogenesis. Pro-oxidants induce Car’ release from mitochondria, which may be 
followed by Ca2’ ‘ cycling’, collapse of dw, and ATP depletion. Under these conditions the cellular Car’ homeostasis cannot be maintained, the 
cytosolic Ca2+ level rises, and cells go into apoptosis. The pro-oxidant-induced Car’ release is prevented by antioxidants (e.g. catalase), or by 
compounds which prevent protein mono(ADPribosyl)ation m mitochondria (e.g. cyclosporin A or m-iodobenzylguanidine). Ca*’ re-uptake is 
prevented by Ruthenium red or Ca2+ chelators. The protein encoded for by the proto-oncogen bcl-2 stabilizes dy, thereby limiting ATP depletion 
and the disturbance of the cellular Ca*’ homeostasis. Inhibition of apoptosis (e.g. by overexpression ofbcl-2) may confer increased survival potential 
to cells and thereby favour oncogenesis. Ayl, electrical potential across the inner mitochondrial membrane, negative inside. 
none imine deplete hepatocytes of ATP and kill them 
[8]. Cyclosporin A, a potent inhibitor of the pro-oxi- 
dant-induced Ca*’ release in isolated mitochondria 
[6,7], blocks mitochondrial Ca*+ release and therefore 
excessive Ca2+ cycling also in hepatocytes. Cyclosporin 
A thereby prevents loss of ATP, and keeps the hepato- 
cytes viable [8]. Similar results were reported in [55]. 
Also infection of cells by viruses can result in mitochon- 
drial Ca*+ cycling followed by cell death [56]. Whether 
it occurred by apoptosis was not tested in these experi- 
ments. However, apoptosis is inhibited by cyclosporin 
A in animals, as recently shown by analysis of hormone- 
induced regression of bullfrog tadpole tails [57]. 
6. HYPOTHESIS 
Taken together, these results lead to the hypothesis 
that apoptosis can be triggered by a pro-oxidant-in- 
duced Ca*+ release from mitochondria, as summarized 
in Fig. 1. Ca*’ release causes a direct stimulation of the 
Ca2’-dependent endonuclease(s), and/or a massive dis- 
turbance of the cellular Ca*’ homeostasis due to mito- 
chondrial Ca*’ cycling, ATP depletion, and inhibition 
of membrane-bound ATPases, which normally remove 
Ca*+ from the cytosol. Accordingly, bcl-2 (and maybe 
other proto-oncogens?) prevents cells from going into 
apoptosis by counteracting the collapse of dly and its 
fatal consequences. The proposed sequence of events 
also explains the need for NGF for growth of neurons 
in cell culture because NGF provides catalase and 
thereby lowers the level of hydrogen peroxide, a stimu- 
lator of mitochondrial Ca*’ release. In addition, the 
hypothesis suggests a causal link between the increased 
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Av and the unlimited growth potential of many carci- 
noma and possibly other cancer cells. 
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